An article from Nikkei, looks like we have more arsenal to fight the influenza virus :
" TOKYO : Daiichi Sankyo Co. Ltd. said Friday its influenza treatment, Inavir, has been approved in Japan, becoming the second product in the new generation of influenza drugs to be commercialized in the country.
The Tokyo-based pharmaceutical maker expects Inavir--also known by the generic name laninamivir--to be a competitive alternative to existing products such as Tamiflu from Roche Holding AG (ROG.VX) and Relenza from GlaxoSmithKline PLC., for treatment of infections from both the conventional flu and swine flu virus.
Inavir is administered through a small inhaling device, as is GSK's Relenza. But patients need to take it only once. Relenza needs to be taken twice a day for five days."
No comments:
Post a Comment